Trials / Not Yet Recruiting
Not Yet RecruitingNCT06946069
Immunomodulatory Effects of NB-UVB and Steroids in Vitiligo: A Study on CXCL11 and TEMRA Biomarkers
Expression of CXCL11 & TEMRA in Serum of Vitiligo Patients Treated With Narrow-band UVB
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
this is a prospective, randomized controlled trial (RCT) investigating the immunological effects of narrowband UVB (NB-UVB) phototherapy-both as monotherapy and in combination with oral mini-pulse (OMP) steroids-in non-segmental vitiligo patients. The study evaluates changes in CXCL11 (a chemokine involved in T-cell recruitment) and TEMRA (terminally differentiated effector memory T cells re-expressing CD45RA) levels in serum before and after treatment.
Detailed description
Design: Randomized controlled trial (RCT) with two parallel arms. Duration: Six months (including baseline and follow-up assessments). Setting: Outpatient dermatology clinic at Assiut University Hospital, Egypt. Objectives: Compare the immunomodulatory effects of NB-UVB alone vs. NB-UVB + OMP steroids in vitiligo patients. Assess CXCL11 and TEMRA levels as potential biomarkers for disease activity and treatment response. Evaluate clinical repigmentation using Vitiligo Extent Score (VES/VESplus). Methodology: 40 patients with stable non-segmental vitiligo will be enrolled. 20 patients will undergo serum analysis for CXCL11 and TEMRA via ELISA. Treatment arms: NB-UVB monotherapy (twice weekly). NB-UVB + OMP steroids (dexamethasone 2.5-3 mg/week). Follow-up: Clinical and immunological assessments at baseline and 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | NB-UVB twice weekly | Standard phototherapy without additional systemic treatment. |
| OTHER | NB-UVB + dexamethasone (2.5-3 mg/week) | Combination therapy to enhance immunosuppression and repigmentation. |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2025-12-30
- Completion
- 2026-09-30
- First posted
- 2025-04-27
- Last updated
- 2025-04-27
Source: ClinicalTrials.gov record NCT06946069. Inclusion in this directory is not an endorsement.